4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV 22-25 September 2002, San Diego, CA, USA

LIPIDIC ALTERATIONS IN AIDS PATIENTS USING ANTIRETROVIRAL THERAPY REGIMEN CONTAINING LOPINAVIR/RITONAVIR

Antiviral Therapy 2002; 7:L32 (abstract 47)

JE Ribeiro^1,2, JHS Pilotto¹, NAS Santos¹, LO Roy¹, AMH Moreno¹, MLE Pires², AS Souza², AC Varela², CMS Machado², EA Magalhães² and HC Maleh^2
1STD/AIDS-Hospital Geral de Nova Iguaçu(HGNI), Rio de Janeiro, Brazil; ²University of Rio de Janeiro(UNIRIO), Rio de Janeiro, Brazil

BACKGROUND: Among the most frequent metabolic alteration associated with the use of antiretroviral (ARV) are the dislipideousnes (DL). This study evaluates, in AIDS patients (pts) using ARV therapy rescue regimen containing lopinavir/ritonavir (lopinavir/r), the change in triglyceridics (TG), total cholesterol (COL), HDL-cholesterol (HDL) and LDL-cholesterol (LDL) levels.

METHODS: Participants of this study were 20 pts with AIDS of the STD/AIDS Service of the Nova Iguaçú General Hospital (HGNI), both male and female, aged between 25 and 56 years, without familiar and personal history or known causes of DL. The basal seric dosage of TG, COL, HDL and LDL was measured after 14 h of fasting, by the enzymatic method (mg/ml) and after an interval of 12 weeks (20 pts) and 26 weeks (12 of the 20 pts) from starting lopinavir/r. The dates were analysed by the t-test and confidence intervals.

RESULTS: There were no statistically significant diferences among the medians of COL, HDL, LDL and TG of the 20 patients evaluated before and after 12 weeks of using ARV regimen containing lopinavir/r, whilst among the 12 pts evaluated after the 26th week the only statistically significant difference was related to the difference of the median of TG, which was 169.5 mg/dl ±246.57 (P<0.04). The LDL evaluation was impaired by the hypertriglycerids (TG >300 mg/ml) found in five of the 20 pts (41%) evaluated.

CONCLUSION: We have 95% of certainty that the increase of TG related to the whole sample was, in median 12.86-326.16 mg/dl (P<0.04), after 26 weeks of using the medication. We observed that among these last 12 patients, two used efavirenz and two stavudine associated to the regimen containing lopinavir/r, but none of them were among those who showed hypertriglycerids (TG >200mg/ml). The date suggests that the late increase of TG by week 26 seems to be directly related to the use of lopinavir/r in AIDS patients.

Presenting author: JE Ribeiro

2002-09-22
47

Copyright © 2002 - International Medical Press Ltd.. Reproduction of this abstract (other than one copy for personal reference) must be cleared through the Medical Editor, International Medical Press, 36 St Mary-at-Hill, London EC3R 8DU, United Kingdom.